Prevalence and patterns of use of psychoactive medicines among individuals with autism in the Autism Society of Ohio
- PMID: 14594332
- DOI: 10.1023/a:1025883612879
Prevalence and patterns of use of psychoactive medicines among individuals with autism in the Autism Society of Ohio
Abstract
To date, there have been few surveys of psychotropic and antiepileptic drug (AED) prevalence in individuals with autism-spectrum conditions. We surveyed 747 families in the Autism Society of Ohio regarding the use of psychotropic drugs, AEDs, and over-the-counter (OTC) preparations for autism. In all, 417 families (55.8%) replied. A total of 45.6% were taking some form of psychotropic agent (including St. John's wort and melatonin), whereas 11.5% were taking AEDs, and 10.3% took OTC autism preparations. The most common psychotropic agents included antidepressants (21.6%), antipsychotics (14.9%), antihypertensives (12.5%), and stimulants (11.3%). Some 51.6% were prescribed psychotropic drugs or AEDs, and 55.4% took psychotropic drugs, AEDs, or autism supplements. Demographic variables frequently found to be associated with medication use included greater age, more severe autism, more severe intellectual handicap, and housing outside the family home. Whereas there is empirical support for the use of some of these psychotropic agents in autism, others are being prescribed with minimal research support. OTC autism preparations were used in substantial numbers of individuals, despite limited research support and the possibility of toxic effects.
Similar articles
-
Prevalence and patterns of use of psychoactive medicines in individuals with autism in the Autism Society of North Carolina.J Child Adolesc Psychopharmacol. 2002 Winter;12(4):311-21. doi: 10.1089/104454602762599853. J Child Adolesc Psychopharmacol. 2002. PMID: 12625991
-
Medication patterns in patients with autism: temporal, regional, and demographic influences.J Child Adolesc Psychopharmacol. 2005 Feb;15(1):116-26. doi: 10.1089/cap.2005.15.116. J Child Adolesc Psychopharmacol. 2005. PMID: 15741793
-
Psychotropic and anticonvulsant drugs in subjects with autism: prevalence and patterns of use.J Am Acad Child Adolesc Psychiatry. 1995 Dec;34(12):1672-81. doi: 10.1097/00004583-199512000-00018. J Am Acad Child Adolesc Psychiatry. 1995. PMID: 8543539
-
AEDs and psychotropic drugs in children with autism and epilepsy.Ment Retard Dev Disabil Res Rev. 2004;10(2):135-8. doi: 10.1002/mrdd.20026. Ment Retard Dev Disabil Res Rev. 2004. PMID: 15362171 Review.
-
[Review of psychopharmacological treatments in adolescents and adults with autistic disorders].Encephale. 2002 May-Jun;28(3 Pt 1):248-54. Encephale. 2002. PMID: 12091786 Review. French.
Cited by
-
Psychotropic drug treatments for people with autism and other developmental disorders: a primer for practicing behavior analysts.Behav Anal Pract. 2010 Spring;3(1):4-12. doi: 10.1007/BF03391753. Behav Anal Pract. 2010. PMID: 22479667 Free PMC article.
-
Problem behaviours and caregiver burden among children with Autism Spectrum Disorder in Kuching, Sarawak.Front Psychiatry. 2023 Oct 30;14:1244164. doi: 10.3389/fpsyt.2023.1244164. eCollection 2023. Front Psychiatry. 2023. PMID: 37965356 Free PMC article.
-
Age-related variation in health service use and associated expenditures among children with autism.J Autism Dev Disord. 2013 Apr;43(4):924-31. doi: 10.1007/s10803-012-1637-2. J Autism Dev Disord. 2013. PMID: 22941343 Free PMC article.
-
Report of the ABAI Task Force on Contingent Electric Skin Shock.Perspect Behav Sci. 2023 Jun 15;46(2):261-304. doi: 10.1007/s40614-023-00379-w. eCollection 2023 Jun. Perspect Behav Sci. 2023. PMID: 37425985 Free PMC article. Review.
-
Brief report: retrospective case series of oxcarbazepine for irritability/agitation symptoms in autism spectrum disorder.J Autism Dev Disord. 2013 May;43(5):1243-7. doi: 10.1007/s10803-012-1661-2. J Autism Dev Disord. 2013. PMID: 22976374
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources